A Dexcom (NSDQ:DXCM) communication on its website states that it will soon cease manufacturing for its G6 continuous glucose ...

DexCom (NASDAQ:DXCM) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...

Fintel reports that on December 11, 2025, Citigroup maintained coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation.

DexCom has enormous runway for growth, not just in its home market - the U.S., but internationally as well. Manufacturing efficiencies could support their international ambitions while supporting ...

Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q3 2025 investor letter.

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

Dexcom, a global leader in real time continuous glucose monitoring for people with diabetes, is releasing the Dexcom G6 mobile app in Spanish, available immediately for users with a compatible iOS (v1 ...

The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...

Wondering if DexCom stock is a hidden bargain or just riding a wave? You are not alone, and today's market swings only add to the intrigue. DexCom shares have jumped 5.4% over the past week even after ...

Dexcom G6 gives people with diabetes the power to manage their condition without fingersticks* or scanning Proven to improve glycemic control and can reduce the risk of costly long-term ...

MADRID--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM), announced today the Dexcom G6 CGM System has received the CE Mark for use during pregnancy in ...